ArticleAntimicrobial agents and chemotherapy2001
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.
Article in Antimicrobial agents and chemotherapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 93 citations in OpenAlex.
- Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.Antimicrobial agents and chemotherapy · 2014Article
- Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype.Hepatology international · 2013Article
- Stable replication of the EBNA1/OriP-mediated baculovirus vector and its application to anti-HCV gene therapy.Virology journal · 2009Article
- Substituted imidazopyridines as potent inhibitors of HCV replication.Journal of hepatology · 2009Article
- Understanding the molecular basis of HBV drug resistance by molecular modeling.Antiviral research · 2008Article
- Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.Gastroenterology · 2008Review
- The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro.Antimicrobial agents and chemotherapy · 2007Article
- Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.Antimicrobial agents and chemotherapy · 2006Article
- Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma.World journal of gastroenterology · 2006Article
- Baculovirus as a highly efficient expression vector in insect and mammalian cells.Acta pharmacologica Sinica · 2005Review
- Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.Antimicrobial agents and chemotherapy · 2004Article
- Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.Journal of virology · 2004Article
- The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.Journal of virology · 2003Article
- Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.Antimicrobial agents and chemotherapy · 2003Article
- Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro.Antimicrobial agents and chemotherapy · 2002Article
- Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus.Antimicrobial agents and chemotherapy · 2002Article
- Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.Antimicrobial agents and chemotherapy · 2002Article
- In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.Antimicrobial agents and chemotherapy · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
Abstract
Long-term nucleoside analog therapy for hepatitis B virus (HBV)-related disease frequently results in the selection of mutant HBV strains that are resistant to therapy. Molecular studies of such drug-resistant variants are clearly warranted but have been difficult to do because of the lack of convenient and reliable in vitro culture systems for HBV. We previously developed a novel in vitro system for studying HBV replication that relies on the use of recombinant baculoviruses to deliver greater than unit length copies of the HBV genome to HepG2 cells. High levels of HBV replication can be achieved in this system, which has recently been used to assess the effects of lamivudine on HBV replication and covalently closed circular DNA accumulation. The further development of this novel system and its application to determine the cross-resistance profiles of drug-resistant HBV strains are described here. For these studies, novel recombinant HBV baculoviruses which encoded the L526M, M550I, and L526M M550V drug resistance mutations were generated and used to examine the effects of these substitutions on viral sensitivity to lamivudine, penciclovir (the active form of famciclovir), and adefovir, three compounds of clinical importance. The following observations were made: (i) the L526M mutation confers resistance to penciclovir and partial resistance to lamivudine, (ii) the YMDD mutations M550I and L526M M550V confer high levels of resistance to lamivudine and penciclovir, and (iii) adefovir is active against each of these mutants. These findings are supported by the limited amount of clinical data currently available and confirm the utility of the HBV-baculovirus system as an in vitro tool for the molecular characterization of clinically significant HBV strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.